construction, renovation, the lease of passenger vehicles, the development of major software applications, or supplanting current applicant expenditures.

The National Center for Injury Prevention and Control of CDC will provide information on submitting applications via the Rape Prevention and Education Version of the Grant Application and Reporting System (RPE–GARS).

DATES: Awards will begin on or about October 1, 2001, and will be made for a 12-month budget period within a project period of up to five years.

Comments are due June 4, 2001.

ADDRESSES: Interested persons are invited to comment on the proposed program. All comments received on or before June 4, 2001 will be considered before the final program announcement is published. Address comments to: Wendy Watkins, Division of Violence Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE, Mailstop K–58, Atlanta, GA 30341–3724, Telephone (770) 488–1567, Internet address: *dmw7@cdc.gov.*

FOR FURTHER INFORMATION CONTACT: Wendy Watkins, Division of Violence Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE, Mailstop K–58, Atlanta, GA 30341–3724, Telephone (770) 488–1567, Internet address: dmw7@cdc.gov.

Dated: April 27, 2001.

Joseph R. Carter,

Associate Director for Management and Operations,, Centers for Disease Control and Prevention (CDC).

[FR Doc. 01–11068 Filed 5–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Request for Input on Vaccine Financing

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS).

ACTION: Notice and request for public comment.

SUMMARY: The National Vaccine Advisory Committee (NVAC) Work Group on the Introduction of New Vaccines seeks input on issues that may be barriers to the optimal implementation of new vaccines. The work group is evaluating how vaccine financing affects the standard of care for different population subgroups.

Vaccine financing can impact specific population subgroups differentially in terms of access and supply of new vaccines. The process by which the public and private sector purchase and distribute vaccines may differ in important ways. The public sector plays a major role in the financing of pediatric vaccine, but it plays a smaller role in the financing of adult vaccines. The timing of public purchase may depend on specific advisory group recommendations as well as specific state budgets. The eligibility for public and private payer programs may also vary.

We are asking partner organizations and groups to submit their items on the pluses and minuses of the current vaccine financing system. In addition to identifying potential barriers to the optimal implementation of vaccines due to vaccine financing, possible solutions to these problems are requested. The information gathered from the partners will be used as the basis for a meeting to develop options for the NVAC to consider.

DATES: Comments and information must be submitted by May 31, 2001.

ADDRESSES: Comments and information regarding Vaccine Financing should be submitted to the National Vaccine Program Office, Attn: Introduction of New Vaccines, Centers for Disease Control and Prevention, Mailstop D–66, 1600 Clifton Road, NE., Atlanta, Georgia 30333; Federal Express Address: 200 E. Ponce de Leon Avenue, Decatur, Georgia 30030; fax: 404–687–6687; e-mail: *nvpo@cdc.gov.*

FOR FURTHER INFORMATION CONTACT: The National Vaccine Program Office, Attn: Introduction of New Vaccines, Centers for Disease Control and Prevention, Mailstop D–66, 1600 Clifton Road, NE., Atlanta, Georgia 30333; Federal Express Address: 200 E. Ponce de Leon Avenue, Decatur, Georgia 30030; fax: 404–687–6687; e-mail: *nvpo@cdc.gov.*

Dated: April 27, 2001.

Joseph R. Carter,

Associate Director for Management and Operations, Centers for Disease Control and Prevention.

[FR Doc. 01–11067 Filed 5–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N–0183]

Elanco Animal Health, A Div. of Eli Lilly & Co. et al.; Withdrawal of Approval of NADAs

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 13 new animal drug applications (NADAs) listed below at the request of the sponsor. In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations by removing the portions reflecting approval of the NADAs.

DATES: Withdrawal of approval is effective May 14, 2001.

FOR FURTHER INFORMATION CONTACT: Pamela K. Esposito, Center for Veterinary Medicine (HFV–210), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–5593.

SUPPLEMENTARY INFORMATION: The following sponsors have requested that FDA withdraw approval of the NADAs listed below because the products are no longer manufactured or marketed:

Sponsor	NADA Number Product (Drug)	21 CFR Cite Affected (Sponsor Drug Labeler Code)
Elanco Animal Health, A Div. of Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285.	NADA 12–585 Tylan Injectable (tylosin tartrate).	522.2640b (000986)
.....	NADA 15–207 Hyferdex Injection (iron dextran complex).	522.1183(c) (000986)

Sponsor	NADA Number Product (Drug)	21 CFR Cite Affected (Sponsor Drug Labeler Code)
.....	NADA 30–330 Tylocine Sulfa Tablets (sulfadiazine, sulfamerazine, sulfamethazine, tylosin).	not applicable
.....	NADA 31–962 Tylan plus Neomycin Eye Powder (neomycin sulfate, tylosin).	524.2640 (000986)
.....	NADA 40–123 Toptic Ointment (cephalonium, flumethasone, iodochlorhydroxyquin, piperocaine hydrochloride, polymyxin B sulfate).	524.321 (000986)
.....	NADA 47–092 Tribodine (ticarbodine)	520.2460a (000986)
.....	NADA 47–353 Ferti-Cept (chorionic gonadotropin).	522.1081(b) (000986)
.....	NADA 92–602 Cephalothin Discs (cephaloridine).	529.360 (000986)
.....	NADA 96–678 Tribodine Capsules (ticarbodine).	520.2460b (000986)
Bioproducts, Inc., 320 Springside Dr., suite 300, Fairlawn, OH 44333–2435.	NADA 93–518 Tylan® 10 Plus (tylosin phosphate).	558.625(b)(2) (051359)
Young's Inc., Roaring Spring, PA 16673	NADA 96–162 Hog Grow-R-Mix-4000, Hog Grow-R-Mix–800 (tylosin phosphate).	558.625(b)(13) (035393)
Veterinary Laboratories, Inc., 12340 Santa Fe Dr., Lenexa, KS 66215.	NADA 42–889 Oxytocin Injection (oxytocin)	522.1680(b) (000857)
Webel Feeds, Inc., R.R. 3, Pittsfield, IL 62363 ...	NADA 116–196 Webel Tylan Premix (tylosin phosphate).	558.625(b)(73) (035098)

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADAs 12–585, 15–207, 30–330, 31–962, 40–123, 42–889, 47–092, 47–353, 92–602, 93–518, 96–162, 96–678, and 116–196, and all supplements and amendments thereto, is hereby withdrawn, effective May 14, 2001.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations by removing those portions that reflect approval of the NADAs.

Dated: April 23, 2001.

Linda Tollefson,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. 01–11071 Filed 5–2–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Single Source Cooperative Agreement to Support the National Center for Natural Products Research (NCNPR), University of Mississippi

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its intention to accept and consider a single source application for the award of a cooperative agreement to the University of Mississippi (UM) to support the National Center for Natural Products Research (NCNPR), which is located on UM's Campus at Oxford, MS. FDA anticipates providing up to $1 million in fiscal year 2001 (direct and indirect costs) for this project, with an additional 4 years of funding up to $1 million per year predicated upon acceptable performance and the availability of future fiscal year funding. These collaborations will support and benefit the public health by promoting more efficient development and dissemination of natural products research and science and will complement the diverse activities of both the public and private sector that may become collaborators.

DATES: Submit applications by June 18, 2001.

ADDRESSES: An application is available from, and should be submitted to Rosemary Springer, Grants Management Specialist, Division of Contracts and Procurement Management (HFA–520), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7182, e-mail: rspringe@oc.fda.gov. Applications hand-carried or commercially delivered should be addressed to rm. 2129, 5630 Fishers Lane, Rockville, MD 20857. Application forms can also be found at http://www.nih.gov/grants/funding/phs398/forms__toc.html.

FOR FURTHER INFORMATION CONTACT:

Regarding the administrative and financial management aspects of this notice: Rosemary Springer (address above).

Regarding the programmatic aspects: Jeanne I. Rader, Center for Food Safety and Applied Nutrition (HFS–840), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–5375, e-mail: JRader@CFSAN.fda.gov.

SUPPLEMENTARY INFORMATION: FDA is announcing its intention to accept and consider a single source application from UM for a cooperative agreement to support NCNPR. FDA's authority to enter into grants and cooperative agreements is detailed under section 301 of the Public Health Service Act (42 U.S.C. 241). FDA's research program is described in the Catalog of Federal Domestic Assistance at 93.103. Before entering into cooperative agreements, FDA carefully considers the benefits such agreements will provide to the public.

The Public Health Service (PHS) strongly encourages all award recipients to provide a smoke-free work place and to discourage the use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.

FDA is committed to achieving the health promotion and disease prevention objectives of Healthy People 2010, a national activity to reduce morbidity and mortality and to improve the quality of life. Applicants may obtain a hard copy of Healthy People 2010 objectives, volumes I and II,